EpiphanyRx, acquired by Navitus in 2021, is Navitus’ in-house specialized solution for self-insured employers with ~3000 lives or less.
Through the acquisition, by leveraging Navitus’ purchasing power, EpiphanyRx clients realized a:
$29 PMPM COST REDUCTION COMPARED TO PROJECTED PRE-AQUISITION COSTS
EpiphanyRx provides a standard suite of products designed to decrease costs and support a rich benefit offering for employers this size.
COST TREND WAS ACHIEVED BY:
- One modular, cost-effective formulary designed to drive results
- Strategies to lower member and plan cost on both traditional and specialty drugs
A LOOK BACK
Targeted immunomodulators (TIMs) and diabetes were also the two primary drug class cost drivers for specialty and non-specialty respectively. 
Moving forward, programs to drive down costs for these two drug classes are a key focus.
To learn more, visit epiphanyrx.com
1Net total cost paid by plans and members minus manufacturer rebates